These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36632330)

  • 1. Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.
    Wang X; Guo Z; Wu X; Chen D; Wang F; Yang L; Luo M; Wu S; Yang C; Huang L; Fu L
    Immunotargets Ther; 2023; 12():1-16. PubMed ID: 36632330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
    Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.
    Kim KH; Hur JY; Koh J; Cho J; Ku BM; Koh JY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ; Shin EC
    Immune Netw; 2020 Dec; 20(6):e48. PubMed ID: 33425433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
    Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
    Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
    Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
    Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer.
    Cao S; Zhang Y; Zhou Y; Rong W; Wang Y; Ling X; Zhang L; Li J; Tomita Y; Watanabe S; Nakada T; Seki N; Hida T; Dermime S; Zhong R; Zhong H
    Transl Lung Cancer Res; 2022 Apr; 11(4):607-616. PubMed ID: 35529793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
    Rocha P; Ramal D; Ripoll E; Moliner L; Corbera A; Hardy-Werbin M; Orrillo M; Taus Á; Zuccarino F; Gibert J; Perera-Bel J; Casadevall D; Arriola E
    JTO Clin Res Rep; 2021 Jan; 2(1):100115. PubMed ID: 34589976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer.
    Huang H; Chen Y; Weng X; Li S; Zhang L; Chen P
    Cancer Cell Int; 2022 Aug; 22(1):261. PubMed ID: 35989349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
    Chen S; Han L; Guo S; Tan Z; Dai G
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy.
    Wang X; He Z; Liu W; Han R; Li H; Dai S; Zhang L; Mao M
    J Oncol; 2022; 2022():9030782. PubMed ID: 35571492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
    Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
    Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.